首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >Nitrated apolipoprotein A-I, a potential new cardiovascular marker, is markedly increased in low high-density lipoprotein cholesterol subjects.
【24h】

Nitrated apolipoprotein A-I, a potential new cardiovascular marker, is markedly increased in low high-density lipoprotein cholesterol subjects.

机译:在低高密度脂蛋白胆固醇受试者中,硝化载脂蛋白A-I(一种潜在的新的心血管标志物)显着增加。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Oxidative stress plays an important role in the pathogenesis of coronary artery disease. Recent work showed that high-density lipoproteins isolated from atherosclerotic lesions and blood of patients with established coronary artery disease contain elevated levels of nitrated apolipoprotein A-I. Methods to quantify nitrated apolipoprotein A-I in the plasma may facilitate in the determination of a correlation between plasma levels of nitrated apolipoprotein A-I and risk of atherosclerosis. METHODS: In this report, the presence of plasma nitrated apolipoprotein A-I in subjects with cardiovascular disease was detected by Western blot analysis and quantified by a newly developed specific sandwich enzyme-linked immunosorbent assay. RESULTS: The precision of the assay was indicated by the good correlation obtained between enzyme-linked immunosorbent assay and Western blot (r(2)=0.96). Using these two methods, we were able to detect significant elevations (3-fold increase) of plasma nitrated apolipoprotein A-I in low high-density lipoprotein cholesterol subjects as compared to high-density lipoprotein cholesterol subjects. In addition, we found that both plasma and serum samples can be used by enzyme-linked immunosorbent assay to quantify nitrated apolipoprotein A-I concentrations. More importantly, the degree of nitrated apolipoprotein A-I-containing high-density lipoprotein particles was negatively correlated with levels of circulating apolipoprotein A-I. CONCLUSIONS: Measurement of nitrated apolipoprotein A-I levels by this rapid and reproducible new method has the advantages of great sensitivity with no sample manipulations, thus we suggest that this novel method could be useful to monitor levels of circulating nitrated apolipoprotein A-I in order to investigate its value as a potential biological marker for inflammatory vascular disease.
机译:背景:氧化应激在冠心病的发病机理中起着重要作用。最近的工作表明,从已确诊的冠心病患者的动脉粥样硬化病变和血液中分离出的高密度脂蛋白含有较高水平的硝化载脂蛋白A-I。定量血浆中硝化载脂蛋白A-I的方法可能有助于确定血浆硝化载脂蛋白A-I与动脉粥样硬化风险之间的相关性。方法:在此报告中,通过蛋白质印迹分析检测了患有心血管疾病的受试者血浆中硝酸化的载脂蛋白A-1的存在,并通过新开发的特异性夹心酶联免疫吸附法对其进行了定量。结果:酶联免疫吸附测定法与蛋白质印迹法之间的良好相关性表明了测定的准确性(r(2)= 0.96)。使用这两种方法,与高密度脂蛋白胆固醇受试者相比,我们能够检测到低硝酸盐高密度脂蛋白胆固醇受试者的血浆硝化载脂蛋白A-1明显升高(增加了3倍)。另外,我们发现血浆和血清样品均可通过酶联免疫吸附测定法用于量化硝化的载脂蛋白A-1浓度。更重要的是,含硝化载脂蛋白A-1的高密度脂蛋白颗粒的程度与循环载脂蛋白A-1的含量呈负相关。结论:这种快速,可重现的新方法测量硝化载脂蛋白AI水平具有灵敏度高,无需样品操作的优点,因此,我们建议该新方法可用于监测循环硝化载脂蛋白AI水平,以研究其价值作为炎症性血管疾病的潜在生物学标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号